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Graft-versus-host disease (GvHD) is the major cause of mor-
bidity and mortality fo llowing bone marrow transplantation 
(BMT). The goal of this study of 69 cyclosporin-treated, 
allogeneic BMT patients was to identify early clinical, labora-
tory, or histopathologic indicators of the development of 
progressive, fatal GvHD. Peak values within 100 d of allo-
geneic BMT for total bilirubin, stool volume in a day, clinical 
stage of cutaneous GvHD (based on extent of rash), and 
overall clinical stage of GvHD (based on a combination of 
graft-versus-host reactions in the skin, liver, and gastrointes-
tinal tract) were most useful (p < 0.05, by logistic regression) 
in identifying those patients with clinically progressive and 
fatal GvHD. Peak values for each of these parameters were 
reached an average of 40 d or less after BMT. Each unit 
increase in peak clinical stage of rash (e.g., stage 2 versus stage 
3) W'as associated with an odds ratio incremental risk of 5.8 
for clinical progression of GvHD, and each tenfold increase 
in peak total bilirubin (e.g., 2 mg/dl versus 20 mg/dl) or stool 
A cute graft-versus-host disease (GvHD) occurs in ap-proximately half of human leukocyte antigen (HLA)-matched recipients of allogeneic bone marrow [1,2] and is the major impediment to successful bone marrow transplantation. Advanced GvHD is easily rec-
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output in a day (e.g., 100 cm3/d versus 1000 cm3jd) was 
associated with an incremental risk of 8.4 and 10.6, respec-
tively, for a fatal outcome from GvHD. Number of exocy-
tosed lymphocytes and dyskeratotic epidermal keratinocytes 
(DEK) per linear millimeter of epidermis, the presence of 
follicular involvement, and the degree of dermal perivascular 
lymphocytic infiltration in 121 skin biopsy specimens were 
not associated with the development of progressive or fatal 
GvHD. Pretransplant total body irradiation was associated 
(p = 0.03, by Mann-Whitney U testing) with an increased 
number of 0 EK in skin biopsy specimens taken less than 20 d 
after BMT. This study demonstrates that monitoring of total 
bilirubin, stool output, extent of rash, and overall clinical 
stage of GvHD is most useful during the first 40 dafter BMT 
in formulating the prognosis of early acute GvHD in allo-
geneic BMT patients receiving cyclosporin.] Invest Dermatol 
99:397 -402, 1992 
ognized clinically and histologically, but responds poorly to thera-
peutic intervention with immunosuppressive agents, resulting in 
high morbidity and mortality [3] . Early diagnosis of acute GvHD 
and prompt institution of therapy may improve the outcome of 
affected patients. Therapeutic intervention for GvHD, however, 
may introduce additional immunosuppressive drug - related morbid-
i~ and mortality. Therefore, it is advantageous to identify patients 
With early acute GvHD who will develop progressive and fatal 
GvHD in order to maximize their therapy relative to those with 
milder disease. 
Histopathologic changes in the epidermis, in conjunction with a 
cutaneous eruption, may be the only signs of early GvHD; liver and 
gastrointestinal (GI) tract involvement, if they occur, usually follow 
cutaneous disease. Interpretation of skin biopsy specimens is a stan-
dard method for confirming clinically suspect GvHD [4,5]. Skin 
tissue is useful in models designed to predict the development of 
GvHD prospectively in donor-recipient pairs [6]. Histopathologic 
criteria for the diagnosis of acute cutaneous GvHD, however, were 
developed before the widespread use of cyclosporin A (CsA) [7]. 
Smce the introduction of prophylactic CsA therapy, the value of 
skin biopsy specimens in detecting early GvHD has been questioned 
[8,9]. CsA profoundly alters intra-thymic T-cell maturation as well 
as the expression ofT cell- mediated immunologic events in periph-
eral tissues [2,10,11]. This study was done to identify histopatho-
logic parameters in skin biopsy specimens, and clinical and/or labo-
ratory indicators of skin, liver, and/or gastrointestinal (GI) tract 
injury that are useful in the early diagnosis of acute GvHD in allo-
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Table I. Patient Data 
Outcome' 
Diagnosis' Number of Patients Mean Age (years) Number of Skin Biopsies Preparative Regimenb HP CP D 
ALL 5 23 9 CY, TBI 2 2 0 
3 9 4 BU, CY, VP-16 0 0 0 
AML 8 30 12 BU,CY 3 4 3 
1 29 2 BU, CY, VP-16 1 1 1 
AA 2 27 5 CY, CsA 1 1 1 
CML 20 35 34 CY,TBI 2 9 7 
17 33 36 BU,CY 7 9 6 
4 40 5 BU, CY, VP-16 2 2 1 
HO 1 23 1 BU, CY, VP-16 0 0 0 
MM 1 41 1 BU,CY 0 1 0 
MOS 3 39 6 BU,CY 1 1 1 
NHL 2 34 2 CY, TBI 0 1 0 
1 36 3 BU,CY 0 0 0 
SO 1 5 1 BU,CY 0 0 0 
Totals 69 121 19 31 20 
• ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; AA, aplastic anemia; CML, chronic myelogenous leukemia; HD, Hodgkin's disease; MM, multiple 
myeloma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; SO, storage disease (Maroteaux-Lamy). 
I BU, busulfan; CsA, cyclosporin A; CY, cyclophosphamide; VP-16, etoposide; TEl, total body irradiation. 
, HP, histopathologic progressor; CP, clinical progressor; 0, death from GvHD. 
geneic bone marrow transplant (BMT) patients receiving CsA, and 
which identify those patients who will develop progressive, fatal 
GvHD. 
MATERIALS AND METHODS 
Patient Pop~lation Sixty-nine patients who received an allo-
geneic BMT at the Johns Hopkins Oncology Center between June 
I, 1989 and June 30, 1991 were included in this study (Table I) . 
These patients were selected from among the 92 recipients of an 
allogeneic BMT during this time period, on the basis of the presence 
of histopathologic changes (Table II, vacuolation at the epidermal 
basement membrane [grade 1] and/or basal vacuolation plus dysker-
atosis of epidermal keratinocytes [grade 2]) in a skin biopsy speci-
men taken within 100 d of BMT. The BMT preparative regimen 
(Table I) consisted of 1) cyclophosphamide 50 mg/kg/d for 4 d, 
followed by total body irradiation (TEl) 300 R/d for 4 d; 2) busul-
fan 4 mg/kg/d for 4 d, then cyclophosphamide; or 3) busulfan, 
cyclophos(>hamide 50 mg/kg/ d for 3 d, and etoposide 10 mg/kg/ d 
for 3 d [12J. All patients were started on intravenous CsA 2 d before 
BMT, and were maintained on intravenous and/or oral CsA for 6 
months after BMT. Methylprednisolone (initial dose 2.5 mg/kg/ d) 
was begun for a cutaneous eruption covering greater than 25% of 
total body surface area, or suspicion of liver or GI tract graft-versus-
host reaction (GvHR). All but six patients required initiation of 
methylprednisolone therapy. 
Skin Biopsy Specimens Skin biopsy specimens were obtained 
initially when onset of a macular and papular eruption raised clinical 
suspicion of the presence of cutaneous GvHR. Ninety-four addi-
tional followup specimens were obtained upon recrudescence or 
persistence of ~he eruption beyond 4 to 7 d despite therapeutic in-
Table II. Histopathologic Grades of Acute Cutaneous 
Graft-Versus-Host Reaction' 
Grade Definition 
1 Focal or diffuse vacuolar alteration of basalar epidermal cells 
2 Vacuolar alteration of basal cells; spongiosis and dyskeratosis of 
epidermal cells 
3 Formation of subepidermal cleft in association with spongiosis 
and dyskeratosis 
4 Complete loss of epidermis 
• Adapted from Lerner et al [7]. 
tervention with methylprednisolone. All specimens were obtained 
within 100 d ofBMT by 3- or 4-mm-diameter punch biopsies into 
locally anesthetized (1 % lidocaine) skin, fixed immediately in 10% 
formalin, embedded in parrafin, stained with hematoxylin-eosin 
stain, and examined by light microscopy. 
Skin Biopsy Parameters The histopathologic parameters that 
were determined on each specimen included 1) the number of exo-
cytosed lymphocytes (EL); 2) the number of dyskeratotic epidermal 
keratinocytes (DEK) per linear millimeter of epidermis; 3) the pres-
ence of follicular involvement (one or more EL or DEK within a 
follicle); 4) the presence of satellite lymphocytes (SL) adjacent to or 
surrounding DEK; and 5) the degree of dermal perivascular lym-
phocytic infiltration, scored on a relative scale ofO to 3, with 0 being 
no lymphocytes noted in the papillary dermis, 1 being few (one to 
four) lymphocytes per perivascular area, 2 being moderate (5 to 20), 
and 3 being marked (> 20). These parameters were selected because 
previous studies have suggested they are useful indicators of the 
presence of cutaneous GvHR [13 -19]. Two investigators (GLD, ' 
TDH) read each specimen independently, without knowledge of 
patient diagnosis, preparative regimen, clinical condition, therapeu-
tic intervention, or outcome. Discrepancies between investigators 
occurred for 15% of the determinations, and were resolved by read-
ing the specimen again together. The histopathologic grading sys-
tem employed is detailed in Table II. 
Clinical Parameters Clinical parameters obtained on the day of 
skin biopsy included aspartate transaminase (AST) , alanine transami-
nase (ALT) , alkaline phosphatase, total bilirubin, and volume of 
stool (cm3/ d). These values were used to categorize patients accord-
ing to their clinical stage of organ-specific GvHR in the liver and GI 
tract (Table III) [1,20]. The clinical stage of cutaneous GvHR was 
scored according to the extent of rash at the time of biopsy (Table 
III) . The overall clinical stage of GvHD was determined by com-
bining the histopathologic grade of the specimen with the GvHR 
for the patient in the skin, liver, and GI tract (Table IV) [1,21]. Peak 
values for total bilirubin, stool output in a day, histopathologic 
grade of cutaneous GvHR, clinical stage of cutaneous GvHR, and 
overall clinical stage of GvHD up to the time of biopsy and during 
the first 100 dafter BMT were noted. The peak total bilirubin 
within 21 d ofBMT was also recorded as a potential indicator of the 
presence of venoocclusive disease [22]. Time-interval values for the 
number of d after BMT « 101 d) to onset of rash, earliest histopath-
ologic grade 2 skin biopsy specimen, and peak total bilirubin were 
also recorded . 
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Table III. Clinical Stage of Graft-Versus-Host Reaction by 
Organ System' 
Stage 
1 
2 
3 
4 
Acute Graft-versus-Host Reaction 
Cutaneous, 
Extent of Rash 
(% of body 
surface area) 
< 25 
25 to 50 
> 50 (erythroderma) 
Bullae or desquamation 
Liver, 
Total Bilirubin 
(mg/dl) 
2.0-3.4 
3.5-7.9 
8.0-14.9 
15.0 + 
• From Glucksberg et 01 [1] and Vogelsang and W agner [20]. 
GI Tract, 
Stool Volume 
(cmJ/d) 
500-1000 
1000-1500 
1500-2500 
2500 + 
Patient Outcome Variables A patient was defined as having 
histopathologically progressive GvHD if an initial skin biopsy speci-
men had histopathologic grade 1 or 2 changes and was followed by a 
specimen with a higher histopathologic grade, indicative of worsen-
ing skin involvement. Patients without histopathologic progression 
were those with grade 1 or 2 changes on an initial specimen, fol-
lowed either by no biopsy (i.e., the patient's clinical condition, 
incl uding extent of rash, improved) or subsequent specimen(s) with 
an equivalent or lower grade. Patients with clinically progressive 
GvHD were defined as having an increasingly severe erythematous 
rash despite first- line therapy for GvHD with methylprednisolone. 
In patients without clinically progressive GvHD, the rash remitted 
following treatment with low-dose methylprednisolone. Because 
we vvished to examine potential prognostic indicators of GvHD, 
only initial specimens were included in analyses of histopathologic 
or clinical progression. Patient survival, assessed up to 30 months 
after BMT, was recorded as a binary variable, based on whether or 
not GvHD contributed directly to the patient's death. 
Statistical Analysis Each biopsy and clinical parameter (indepen-
dent variable) was analyzed as a function of each patient outcome 
variable (dependent variable) to identify parameters that were pre-
dictive of patient outcome. Data for initial specimens (n = 69) and 
all specimens (n = 121) were analysed separately; because there was 
only one data point per patient for peak values within 100 d ofBMT 
or time-interval values for clinical parameters, these parameters 
were not included in analyses involving all specimens. Values for 
DEK, EL, alanine transaminase (ALT) , aspartate transaminase 
(AST), alkaline phosphatase, total bilirubin, peak total bilirubin, 
stool volume, and peak stool volume were normalized by logarith-
mic transformation. Analyses employed were univariate chi-square 
analysis, using Yates' continuity correction, when examining a bi-
nary categorical parameter (e.g ., presence or not of SL), or logistic 
regression when analyzing a categorical parameter with more than 
two categories (e.g., degree of perivascular lymphocytic infiltra-
tion) or a continuous parameter (e.g., number of EL). In addition, 
the biopsy parameters for the one specimen per patient with the 
highest histopathologic grade of cutaneous GvHR or, secondarily, 
with the highest number of DEK and EL if two specimens had an 
equivalent histopathologic grade, were analyzed with respect to 
patient survival. Biopsy specimens with an outlying number (at least 
two interquartile distances above the median) of EL (> 19 per mm) 
or both DEK (> 5 per mm) and EL (> 19 per mm) (n = 11) were 
identified. These specimens, and specimens with primarily pilose-
baceous (n = 11) or eccrine (n = 6) inflammation, and minimal 
involvement of the remainder of the epidermis, were analyzed by 
chi-square analysis for their association with the patient outcome 
variables. The association of TBI with the presence of DEK in 
initial specimens and in the one specimen per patient with the 
highest number of DEK was examined by the Mann-Whitney U 
test because DEK distribution had a large number of zero values, but 
was otherwise skewed to the right. The association between treat-
ment with TBI and patient outcome variables was examined by 
chi-square analysis. The effect of time after BMT on the association 
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of TBI with the number of DEK was also assessed separately by 
Mann-Whitney U analysis, including specimens taken less than 
20 dafter BMT, or specimens taken 20 or more dafter BMT. To 
assess whether venoocclusive disease was associated with TBI, the 
peak total bilirubin value during the first 21 dafter BMT was ana-
lysed for initial specimens using the Mann-Whitney U test. Explor-
atory data analysis was performed using the SYGRAPH graphics pack-
age [23], and the GRAPH module of SYSTAT [24]. Data analysis was 
completed using SYSTAT, STATS, NONLlN, TABLES, and NPAR modules. 
RESULTS 
Patient Data Nearly two thirds (59%) of the 69 patients in this 
study required an allogeneic BMT for treatment of chronic myelog-
enous leukemia; half (49%) of these patients received TBI as part of 
their preparative regimen (Table I). The remainder of the patients 
had one of eight other conditions for which BMT was indicated. 
Overall, 27 patients (39%) received TBI. Patient age ranged from 3 
to 55 years. Onset of macular and papular eruption and time of 
initial skin biopsy occurred an average of 10.7 ± 0.7 and 15.7 ± 
1.2 d (mean ± standard error), respectively, after BMT. Peak 
GvHR in the skin (based on extent of rash), GI tract (based on stool 
volume in a day), and liver (based on total bilirubin) occurred 
17.7 ± 1.8,23.6 ± 3.0, and 40.1 ± 3.0 d, respectively, after BMT. 
Overall, 75% of the patients who received an allogeneic BMT dur-
ing the study period (69 of92 patients) developed GvHD, 23% (16 
of 69 patients) developed severe acute GvHD (overall clinical stage 
III or IV GvHD during the first 100 dafter BMT), and 29% (20 of 
69 patients) died during the study period from GvHD and its com-
plications. 
Skin Biopsy Parameters Biopsy parameters, in general, were 
not significantly associated with histopathologic or clinical progres-
sion of GvHD, or death from GvHD. As expected, given the study 
design, a statistically significant association was found between low 
number of DEK (p = 0.05, by logistic regression) or lack of SL 
(p = 0.01, by chi-square analysis) and histopathologic progression 
of GvHD. The initial specimen from patients who subsequently 
developed a higher histopathologic grade of cutaneous GvHR had a 
lower number of DEK and lacked SL more frequently than the 
initial specimen from patients without a subsequent specimen 
showing higher-grade histopathologic cutaneous GvHR. Also, the 
presence of SL was associated with death (p = 0.02, by chi-square 
analysis) from GvHD when the single specimen from each patient 
with the most severe histopathologic cutaneous GvHR was in-
cluded in the analysis. Number ofEL, presence offollicular involve-
ment, degree of dermal perivascular lymphocytic infiltrate, or histo-
pathologic grade of cutaneous GvHR was not associated with any 
patient outcome variable, nor was there a correlation between num-
Table IV. Overall Clinical Stage of Graft-Versus-Host Disease' 
Stage 
o 
II 
lIo 
IIs 
III 
IV 
Combination of Organ-Specific Graft-Versus-Host Reactions 
Clinical cutaneous reaction stage 1 or less, and histopathologic 
grade 2 or less 
Clinical cutaneous reaction stage 2 or 3, and histopathologic grade 
2 or more 
Clinical cutaneous reaction stage 2 to 4, histopathologic grade 2 or 
more, and clinical liver and/or GI tract reaction stage 1 
Clinical liver and/or GI tract reaction stage t to 4, no cutaneous 
reaction 
Clinical cutaneous reaction stage 4, histopathologic grade 2 or 
more, and no liver or GI tract reaction 
Clinical cutaneous reaction stage 2 to 4, histopathologic grade 2 or 
more, and clinical liver and/or GI tract reaction stage 2 to 4; only 
one system grade 3 or greater 
Clinical cutaneous reaction stage 2 to 4, histopathologic grade 2 or 
more, and clinical liver and/or GI tract reaction stage 2 to 4; two 
or more systems stage 3 or greater 
• From Storb and Thomas [21] and Vogelsang and Wagner [20]. 
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Table V. Clinical and Laboratory Parameters Predictive of Clinical Progression of Graft-Versus-Host Disease 
Parameter Progression' Non-Progressiond Odds Ratio' p Value Days After BMTJ 
Peak value within 100 days of BMT (n = 69) 
Total bilirubin (mg/dl)' 6.62 (5.41, 8.11) 
Stool volume (cmJ/d)' 1169 (1047,1306) 
Clinical stage of rash' 3.00 (2.84, 3.16) 
Overall clinical GvHD stage' 2.00 (1.83, 2.16) 
3.56 (2.91, 4.37) 
789 (673, 925) 
2.22 (2.11, 2.32) 
1.27 (1.11, 1.43) 
2.7 (1.0,7.1) 
5.5 (0.9, 32.1) 
5.8 (2.3, 14.9) 
2.2 (1.3, 3.8) 
0.05 
0.05 
0.0004 
0.007 
40.1 (37.1,43.1) 
23.6 (20.6, 26.6) 
17.1 (15.3,18.9) 
18.8 (17.3, 20.2) 
• Geometric mean (± standard error) for clinical or laboratory parameter. 
• Mean (± standard error) for clinical or laboratory parameter. 
, Progressive GvHD. 
, Non-progressive GvHD. 
, Odds ratio (95% confidence interval) of incremental risk, determined by logistic regression, of clinical progression of GvHD for each unit increase in clinical stage of rash or 
overall clinical GvHD stage, or each tenfold increase in total bilirubin or stool volume. 
f Average number of days (± standard error) after BMT when peak value was recorded. 
ber ofEL and overall clinical grade of GvHD. There was no differ-
ence in survival between patients who had histopathologically pro-
gressive cutaneous GvHR compared to those patients who did not. 
Patients with a skin biopsy specimen showing an outlying number 
of EL (> 19 per mm) or both DEK (> 5 per mm) and EL (> 19 per 
mm), primarily pilosebaceous inflammation, or primarily eccrine 
inflammation, did not have histopathologically or clinically pro-
gressive GvHD or death from GvHD at a greater frequency than 
those patients with skin biopsy specimens not in these categories. 
Clinical Parameters In contrast to the skin biopsy parameters, 
several clinical parameters were significantly associated with patient 
outcome. Peak values within 100 d ofBMT for total bilirubin, stool 
volume in a day, clinical stage of cutaneous GvHR, and overall 
clinical stage of GvHD (recorded 18.8 ± 1.5 dafter BMT) were 
positively associated (p < 0.05, by logistic regression) with subse-
quent clinical progression of GvHD (Table V) and death from 
GvHD (Table VI). Higher peak overall clinical stage of GvHD up 
to the time of biopsy (within 15.7 ± 1.2 dafter BMT)(p = 0.05, by 
logistic regression), and overall clinical stage of GvHD on the day of 
biopsy (21.6 ± 1.4 dafter BMT, including all specimens in the 
analysis) (p = 0.02, by logistic regression) were also associated with 
death from GvHD (Table VI). Peak clinical stage of cutaneous 
GvHR (i.e., extent of cutaneous eruption) was the most predictive 
parameter for clinical progression of Gv HD; the odds ratio of incre-
mental risk of clinical progression of GvHD was 5.8 for each unit 
increase in stage of rash (Table V). Peak bilirubin and stool volume 
had the highest predictive value for a fatal outcome from acute 
GvHD; odds ratio of incremental risk for death from GvHD was 8.4 
and 10.6, respectively, for each tenfold increase in these parameters 
(Table VI). Clinical stage of cutaneous GvHR was correlated (p = 
0.04, by logistic regression) with histopathologic grade of GvHR 
when all specimens were analyzed, and peak value for clinical stage 
of cutaneous GvHR within 100 d ofBMT was positively associated 
(p = 0.02, by logistic regression) with histopathologic progression 
of cutaneous GvHR. Overall clinical stage of GvHD, however, was 
negatively associated (p = 0.05, by logistic regression) with histo-
pathologic progression of cutaneous GvHR; patients who subse-
quently developed a higher histopathologic grade of cutaneous 
GvHR had a lower over-all clinical grade of GvHD on the day of 
initial biopsy than those patients who did not progress histopatho-
logically. Values for AST, ALT, alkaline phosphatase, or number of 
days after BMT « 101 d) to onset of rash, earliest histopathologic 
grade 2 skin biopsy specimen, and peak total bilirubin were not 
different with respect to ~ny of the patient outcome variables. Signif-
icantly more (p < 0.001, by chi-square analysis) patients who died 
from GvHD had clinica.lly progressive GvHD than those patients 
who were survivors. 
Preparative Regimen Patients who received TEl as part of their 
preparative regimen had significantly more DEK than patients who 
were not irradiated, whether the initial specimen (p = 0.004, by the 
Mann-Whitney U test) (length of time from BMT to skin biopsy 
averaged 15.7 ± 1.2 d) or the one specimen per patient (p = 0.03) 
with the highest number of DEK (length of time from BMT to 
biopsy of the skin averaged 20.4 ± 1.5 d) was examined. TEl was 
associated with an increased number of DEK, however, only in 
specimens taken less than 20 dafter BMT (p = 0.03), but not in 
specimens obtained 20 d or more after BMT (p = 0.53). Patients 
who received TBI did not have clinically progressive or fatal GvHD 
at a different frequency than those patients who were not irradiated. 
Peak bilirubin during the first 21 dafter BMT, a potential indicator . 
of venoocclusive disease:, was not affected by prior TBI. 
DISCUSSION 
In this study of 69 patients and 121 skin biopsy specimens, we 
identified several early f'redictive clinical and laboratory indicators 
of the development of progressive, fatal GvHD. Parameters that 
Table VI. Clinical and Laboratory Parameters Predictive of Death from Graft-Versus-Host Disease 
Parameter Death' 
Peak value within 100 days of BMT (n = 69) 
Total bilirubin (mg/dl)' 11.40 (8.93,14.55) 
Stool volume (cm3/d)' 1333 (1151, 1545) 
Clinical stage of rash' 2.85 (2.67, 3.03) 
Overall clinical GvHD stage' 2.25 (2.03, 2.47) 
Peak value up to time of biopsy (n = 121) 
Overall clinical stage of GvHD' 1.15 (0.96, 1.35) 
Value at time of biopsy (n = 121) 
Overall clinical stage of GvHD' 1.15 (0.87, 1.43) 
• Geometric mean (± standard error) for clinical or laboratory parameter. 
• Mean (± standard error) for clinical or laboratory parameter. 
, With fatal outcome from GvHD. 
, Without fatal outcome from GvHD. 
Survivald OdJs Ratio' p Value Days After BMTJ 
3.32 (2.84, 3.88) 8.4 (2 .5, 28.5) 0.001 40.1 (37.1,43.1) 
822 (726, 931) 10.6 (1.4,82.8) 0.03 23.6 (20.6, 26.6) 
2.45 (2.35, 2.39) 2.1 (1.0,4.6) 0.05 17.1 (15.3,18.9) 
1.35 (1.21, 1.48) 2.7 (1.5, 5.1) 0.003 18.8 (17.3, 20.2) 
0.65 (0.55, 0.74) 1.4(1.0,2.1) 0.05 15.7 (14.5, 16.9) 
0.69 (0.58·,0.81) 1.6 (1.1, 2.4) 0.02 21.6 (20.2, 23.0) 
, Odds ratio (95% confidence interval) of incremental risk, determined by logistic regression, of death from GvHD for each unit increase in the clinical stage of rash or overall 
clinical stage of GvHD, or each tenfold increase in total bilirubin or stool volume. 
f Average number of days (± standard error) after BMT when clinical or laboratory parameter was recorded. 
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were most useful in identifying those patients with clinically pro-
gressive and ultimately fatal GvHD were total bilirubin, stool vol-
UITle in a day, clinical stage of cutaneous GvHR (i.e. , extent of rash), 
and overall clinical stage of GvHD (Combining GvHR in the skin, 
liver, and GI tract). Although the peak values for these parameters 
within the first 100 dafter BMT were the most useful predictors of 
the progression of, and death from, acute GvHD, higher peak over-
all clinical stage of GvHD up to the time of biopsy, and overall 
clinical stage of GvHD at the time of biopsy were also associated 
with death from GvHD. Peak clinical stage of rash was the most 
predictive parameter for clinical progression of GvHD (odds ratio 
5.8) , and stool volume and total bilirubin had the highest predictive 
value for a fatal outcome from acute GvHD (odds ratio 10.6 and 8.4, 
respectively). Monitoring of total bilirubin, stool volume, clinical 
stage of rash, and overall clinical stage of GvHD yielded the most 
useful prognostic information in the first 40 dafter BMT, as peak 
val ues for each of these parameters were reached an average of 40 d 
or less after BMT. The finding of statistically significant GI and 
hepatic injury in acute GvHD is not surprising, because these organs 
contain target tissues for GvHD effector cells [25 - 27]. 
Histopathologic examination of skin biopsy specimens was of 
little value in identifying those patients who developed clinically 
progressive or ultimately fatal GvHD. Given the utility of clinical 
stage of rash in identifying those patients with progressive and fatal 
acute GvHD, and the correlation of clinical stage of rash with the 
histopathologic grade of cutaneous GvHR, this study demonstrates 
that clinical examination of the patient's skin and staging the extent 
of rash provided more useful prognostic information than the histo-
pathologic parameters. Interpretation of our data, however, is lim-
ited to the predictive value of the various parameters; the data do not 
reflect whether the histopathologic changes observed in the skin 
(Table II) actually represent a GvHR. Thus, interpretation of skin 
biopsy specimens may remain a reliable method of identifying 
GvHD. 
The use of CsA is now a routine part of the transplant regimen of 
allogeneic BMT patients in most centers [28]. CsA profoundly 
alters T-cell maturation and expression of cell-mediated processes 
[10,11], possibly including the acute cutaneous GvHR [2,11 ,29]. 
Histopathologic criteria for GvHD [7] were developed at a time 
when CsA was not used prophylactically; the current utility of these 
criteria in the management of GvHD in allogeneic BMT patients is 
questionable. Several investigators have noted that grade 1 and per-
haps grade 2 histopathologic changes in skin biopsy specimens are 
not specific and are easily confused with radiation and/or cytotoxic 
drug effects [8,9 ,19,30]. This issue has become increasingly impor-
tant as more patients are being treated prophylactically with CsA, 
and a greater percentage of these allogeneic BMT patients appear to 
exhibit primarily lower-grade (lor 2) changes in skin biopsy speci-
ITlens. 
Hymes et al [18] conducted a prognostic study of histopathologic 
features of GvHD in skin biopsy specimens of allogeneic BMT 
patients at the Johns Hopkins Oncology Center during 1977 to 
1982, prior to the routine use of prophylactic CsA. Their patients 
developed severe (stage III or IV) GvHD at a. greater frequency (25 
or 54 patients) than our patients (16 of 69 patients) . Greater density 
of EL (more than 20 EL per high-power field) in the epidermis, and 
rapidity of development of at least a histopathologic grade 2 GvHR 
was significantly associated with development of more severe acute 
GvHD in the patients of Hymes et al [18], but not in our patients. 
These data suggest that there was a limit in our patients, relative to 
those of Hymes et al [18], to the severity of histopathologic changes 
in skin biopsy specimens. The potential for progression of his to path-
ologic GvHD may have been attenuted in the patients of this study 
by use of prophylactic CsA. 
TBI was associated in our study with an increased number of 
DEK in skin biopsy specimens taken within the first 20 dafter 
BMT, suggesting that TBI confounds and lirrilts the utility of deter-
ITlination of the number ofDEK in early skin biopsy specimens. The 
likelihood that histopathologic changes in skin biopsy specimens 
are due to TBI and not to GvHD, howevet:, appears to wane 10 to 
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19 dafter BMT [7,17]' making interpretation of skin biopsy speci-
mens at later time points more meaningful. Unlike our study, Elliott 
et al [19] did not report an increased incidence of epidermal abnor-
malities (i.e., presence of DEK) in patients who had received TBl. 
Although they obtained skin biopsy specimens during a time period 
(14 to 22 dafter BMT) when TBI would be expected to be asso-
ciated with an increase in the number ofDEK, they did not quantify 
number ofDEK, but rather conducted their analysis based simply on 
the presence or absence of DEK in association with prior TBl. 
Histopathologic changes in the skin consistent with criteria for 
grade 2 GvHR have been reported in patients prior to BMT [9], as 
well as in patients with drug-induced cutaneous eruptions [8,31]. 
Thus, the cumulative effects of pre-transplant TBI and intensive 
chemotherapy, plus the prophylactic administration of CsA [29]' 
combine to make the interpretation of skin biopsy srecimens diffi-
cult. The practice of considering any constellation 0 grade 2 histo-
pathologic features as consistent with a cutaneous GvHR oversim-
plifies a complex set of interacting variables. 
Recent studies have focused attention on the possible role of 
follicular stem-cell injury in the genesis of early GvHD and as a 
diagnostic indicator of early GvHD [30,32-34]. In our study, pro-
gression of, or death from, GvHD was not different in subgroups of 
patients with primarily pilosebaceous inflammation, or primarily 
eccrine inflammation compared to patients with more diffuse cuta-
neous GvHR. In agreement with our study, Elliott et al [19] sug-
gested that GvHD-like changes limited to pilosebaceous units have 
a limited capacity for progression and no predictive value for the 
subsequent occurrence of more clear-cut GvHD. Further analysis of 
follicular stem-cell populati~ns, and us~ of immunohistochemical 
cell markers may refine the diagnostic cntena of GvHD in the early 
post-transplant period. Our investigation of clinical, laboratory, and 
histopathologic parameters of GvHD in allogeneic BMT patients 
receiving CsA indicates that monitoring of total bilirubin, stool 
output, extent of rash, and overall clinical stage of GvHD during 
the first 40 dafter BMT is most useful in formulating the diagnosis 
and prognosis of early acute GvHD. 
We thank Dr. Alvaro M,ltJoz for his advice Oil logistic regression data analysis. 
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